These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs. Yuan L, Wang J, Shen WC. J Control Release; 2008 Jul 02; 129(1):11-7. PubMed ID: 18448186 [Abstract] [Full Text] [Related]
14. A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Ravandi F, Estrov Z, Kurzrock R, Breitmeyer JB, Maschek BJ, Talpaz M. Clin Cancer Res; 1999 Dec 02; 5(12):3990-8. PubMed ID: 10632330 [Abstract] [Full Text] [Related]
15. Serum interferon level and (2'-5')oligoadenylate synthetase activity in lymphocytes during clinical interferon application. Lodemann E, Nitsche EM, Lang MH, Gerein V, Altmeyer P, Holzmann H, Kornhuber B. J Interferon Res; 1985 Dec 02; 5(4):621-8. PubMed ID: 2418131 [Abstract] [Full Text] [Related]
16. High level activity of 2', 5'-oligoadenylate synthetase in dog serum. Iwata A, Yamamoto A, Fujino M, Sato I, Hosokawa-Kanai T, Tuchiya K, Ishihama A, Sokawa Y. J Vet Med Sci; 2004 Jun 02; 66(6):721-4. PubMed ID: 15240951 [Abstract] [Full Text] [Related]
17. Native human IFN-alpha is a more potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-alpha. Santak G, Santak M, Forcić D. J Interferon Cytokine Res; 2007 Jun 02; 27(6):481-90. PubMed ID: 17572012 [Abstract] [Full Text] [Related]